A single-center retrospective study to investigate if post-transplant multimodal antibody management protocol (PMAMP) can alter immune response and minimize antibody development of highly sensitized recipients and improving transplant outcomes
Latest Information Update: 11 May 2021
At a glance
- Drugs Antithymocyte globulin (Primary) ; Belatacept (Primary) ; Carfilzomib (Primary) ; Rituximab (Primary)
- Indications Lung transplant rejection
- Focus Therapeutic Use
- 11 May 2021 New trial record
- 28 Apr 2021 Results presented at the 41st Annual Meeting and Scientific Sessions of the International Society for Heart and Lung Transplantation